Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23768796 | 0.85 | ITGB3 (0.56) | L3MBTL1BRD4ITGB3ITGA2B | |
| SCHEMBL30343028 | 0.85 | ITGB3 (0.56) | L3MBTL1BRD4ITGB3ITGA2B | |
| SCHEMBL10165136 | 0.81 | CYP1A2 (0.53) | TP53KMT2APOLBALDH1A1 | |
| SCHEMBL7270138 | 0.78 | KMO (0.56) | TP53POLBALDH1A1 | |
| SCHEMBL29227010 | 0.78 | BRD4 (0.48) | L3MBTL1BRD4ITGB3ITGA2BKMT2A | |
| SCHEMBL8251960 | 0.77 | CYP1A2 (0.46) | L3MBTL1TP53KMT2APOLBALDH1A1 | |
| SCHEMBL30248614 | 0.76 | ITGB3 (0.56) | L3MBTL1BRD4ITGB3ITGA2BKMT2A | |
| SCHEMBL5914800 | 0.76 | ITGB3 (0.56) | L3MBTL1BRD4ITGB3ITGA2BKMT2A | |
| SCHEMBL7278244 | 0.76 | CYP3A4 (0.54) | TP53KMT2APOLBALDH1A1 | |
| SCHEMBL29227030 | 0.75 | ITGB3 (0.54) | L3MBTL1BRD4ITGB3ITGA2BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384268-B1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | CURADEV PHARMA PVT LTD (IN) | 2026-03-18 | — | — | EP | disclosed |
| US-20240360119-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2024-10-31 | — | — | US | disclosed |
| EP-4384268-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | Curadev Pharma Pvt. Ltd. (IN) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023017452-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360119-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | STING1, CGAS, SSB | L3MBTL1 2024/4885BRD4 3318/4885ITGB3 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.